News Pharma Industry

Can a regulatory revamp restore the shine of the ‘pharmacy of the world’ sullied by flaws?


Concept by Vikas Dandekar and Muhabit ul haq

Synopsis

India’s pharmaceutical industry is globally recognized for supplying low-priced drugs and vaccines. But often that reputation is sullied when companies cut corners or ship drugs that fail stringent quality tests. India’s regulatory agencies — which function with a flawed dual central and state structure — are blamed for being corrupt and complicit in such activities. Can a regulatory overhaul change this?

Ever since the pandemic broke out, the sage advice to ‘seize the opportunity in a crisis’ has got a life of its own. It appears to have even shaken up India’s pharma and healthcare authorities to flag off an overhaul of regulations that trace their origin to 1940. However, if indeed a robust regulatory framework is to be built, seriousness of intent would be the most critical element. The health ministry has taken the first step in that

  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

September Special Offer

Get Flat 20% Off

ON ET PRIME MEMBERSHIP

Get Offer

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise



Source link